Evidence map›Paper›PMID 41093994›Full record

ArticleScientific reports2025

SLC25A39 regulates Hedgehog signaling to promote tumor progression and sorafenib resistance in hepatocellular carcinoma.

Qian Qiu, Hehe Yin, Lulu Zhang, Wen Xu, Shiwei Zhu, Qianqian Zhang, Mengqi Zhao, Yuting Qian, Yatong Ruan, Hui Zhang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Qian QiuDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Hehe YinDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Lulu ZhangDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Wen XuDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Shiwei ZhuDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Qianqian ZhangDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Mengqi ZhaoDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yuting QianDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yatong RuanDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Hui ZhangDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Zihao WuDepartment of Geriatrics, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230002, China.
Jiatao LiuDepartment of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui Province, China.
Jing KeDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Ying DaiMedical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Wei WangDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Weijie SunDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu, 233099, China. swj950128@163.com.
Yufeng GaoDepartment of Infectious Diseases, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. aygyf@126.com.
Honghai XuDepartment of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. xuhonghai@ahmu.edu.cn.

Funding

the Department of Education of Anhui Province 2022AH040160 to Y.G.the Department of Education of Anhui Province 2022AH051182 to H.X.the National Natural Science Foundation of Anhui Province 2208085MH204 to Y.G.the National Natural Science Foundation of China 82370608 to Y.G.the National Natural Science Foundation of China 82470626 to H.X.the Research Fund of Anhui Institute of translational medicine 2023zhyx-C55 to H.X.
6 · The paper itself

Abstract

Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC), yet resistance limits its efficacy. The Hedgehog (HH) signaling pathway contributes to drug resistance by maintaining HCC stem cell characteristics, but its role at the single-cell level is underexplored. Utilizing single-cell RNA sequencing (scRNA-seq) and machine learning, we identified solute carrier family 25 member 39 (SLC25A39) as a key regulator of the HH pathway. Analyses of various cohorts revealed that elevated SLC25A39 correlates with poor prognosis in HCC patients. SLC25A39 knockdown inhibited cancer stem cell characteristics and reduced sorafenib resistance in vitro. Furthermore, combined SLC25A39 suppression and sorafenib treatment significantly hindered HCC progression in both in vitro and in vivo models. These findings highlight the potential of shSLC25A39 to enhance sorafenib sensitivity , presenting a new avenue for combating drug resistance and enhancing therapeutic effectiveness.

Indexed as

Carcinoma, HepatocellularDrug Resistance, NeoplasmHedgehog ProteinsLiver NeoplasmsSignal TransductionSorafenibAnimalsAntineoplastic AgentsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHumansMiceNeoplastic Stem CellsXenograft Model Antitumor AssaysAntineoplastic AgentsHedgehog ProteinsSorafenibAcquired resistanceHCCHedgehog signaling pathwayScRNA-seqSLC25A39Sorafenib

Identifiers

PMID41093994
PMCPMC12528477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.